Congressional Activity: Social media discussions have focused on a U.S. representative's recent disclosure of purchasing Gilead Sciences shares on May 6, coinciding with the sale of another healthcare holding. Analysts note the trades were executed across multiple accounts and mirrored patterns seen in prior disclosures. This has prompted commentary on potential signals for the biotech sector.
Pipeline Developments: Users are also highlighting Gilead's recent licensing deals for STAT6 inhibitor programs, positioning the company alongside peers like JNJ in advancing oral therapies. These moves are seen as competitive responses in inflammation research, with data readouts anticipated around mid-2027. Observers emphasize the broader landscape involving multiple players entering similar spaces.
Note: This discussion summary was generated from an AI condensation of post data.
Gilead Sciences Insider Trading Activity
Gilead Sciences insiders have traded $GILD stock on the open market 34 times in the past 6 months. Of those trades, 0 have been purchases and 34 have been sales.
Here’s a breakdown of recent trading of $GILD stock by insiders over the last 6 months:
- DANIEL PATRICK O'DAY (Chairman & CEO) has made 0 purchases and 14 sales selling 296,280 shares for an estimated $41,684,058.
- JOHANNA MERCIER (Chief Comm & Corp Aff Officer) has made 0 purchases and 13 sales selling 68,000 shares for an estimated $9,600,688.
- ANDREW D DICKINSON (Chief Financial Officer) has made 0 purchases and 6 sales selling 18,000 shares for an estimated $2,464,800.
- JEFFREY BLUESTONE sold 5,000 shares for an estimated $617,500
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
Gilead Sciences Revenue
Gilead Sciences had revenues of $7B in Q1 2026. This is an increase of 4.39% from the same period in the prior year.
You can track GILD financials on Quiver Quantitative's GILD stock page.
You can access data on GILD stock through the Quiver Quantitative API.
Gilead Sciences Congressional Stock Trading
Members of Congress have traded $GILD stock 3 times in the past 6 months. Of those trades, 3 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $GILD stock by members of Congress over the last 6 months:
- REPRESENTATIVE JARED MOSKOWITZ has traded it 2 times. They made 2 purchases worth up to $30,000 on 05/06 and 0 sales.
- REPRESENTATIVE JOSH GOTTHEIMER purchased up to $15,000 on 01/27.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard. You can access data on congressional stock trades through the Quiver Quantitative API Congress trades endpoint.
Gilead Sciences Hedge Fund Activity
We have seen 1,067 institutional investors add shares of Gilead Sciences stock to their portfolio, and 1,083 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- FMR LLC added 6,326,800 shares (+9.6%) to their portfolio in Q1 2026, for an estimated $871,516,700
- BLACKROCK, INC. removed 4,184,605 shares (-3.4%) from their portfolio in Q1 2026, for an estimated $576,429,338
- BARCLAYS PLC removed 3,833,287 shares (-42.1%) from their portfolio in Q1 2026, for an estimated $528,035,284
- PACER ADVISORS, INC. removed 3,590,745 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $440,728,041
- BANK OF AMERICA CORP /DE/ removed 3,142,684 shares (-13.6%) from their portfolio in Q1 2026, for an estimated $432,904,721
- QUBE RESEARCH & TECHNOLOGIES LTD removed 2,425,986 shares (-95.2%) from their portfolio in Q1 2026, for an estimated $334,179,571
- WELLINGTON MANAGEMENT GROUP LLP removed 2,369,313 shares (-14.9%) from their portfolio in Q1 2026, for an estimated $326,372,865
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
Gilead Sciences Analyst Ratings
Wall Street analysts have issued reports on $GILD in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Needham issued a "Buy" rating on 02/11/2026
To track analyst ratings and price targets for Gilead Sciences, check out Quiver Quantitative's $GILD forecast page.
Gilead Sciences Price Targets
Multiple analysts have issued price targets for $GILD recently. We have seen 12 analysts offer price targets for $GILD in the last 6 months, with a median target of $165.0.
Here are some recent targets:
- Carter Gould from Cantor Fitzgerald set a target price of $155.0 on 06/16/2026
- Michael Okunewitch from Maxim Group set a target price of $165.0 on 05/20/2026
- Gregory Renza from Truist Securities set a target price of $157.0 on 05/08/2026
- Brian Abrahams from RBC Capital set a target price of $122.0 on 05/08/2026
- Geoff Meacham from Citigroup set a target price of $165.0 on 04/13/2026
- Matthew Harrison from Morgan Stanley set a target price of $175.0 on 04/10/2026
- Akash Tewari from Jefferies set a target price of $180.0 on 03/10/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
